Leuprolide acetate suppresses pedophilic urges and arousability

Archives of Sexual Behavior

Volumn 34, Issue 6, 2005, Pages 691-705

  Schober, Justine M ^a,f   Kuhn, Phyllis J ^b   Kovacs, Paul G ^c   Earle, James H ^d   Byrne, Peter M ^e   Fries, Ruth A ^a  

^a HAMOT MEDICAL CENTER   (United States)

^b Lake Erie Research Institute   (United States)

^c LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^d JHE Consultant Group Inc   (United States)

^e Behavioral Technology Inc   (United States)

^f NONE   (United States)

Author keywords

Leuprolide acetate; Paraphilia; Pedophilia; Sex therapy

Indexed keywords

LEUPRORELIN; PLACEBO; SODIUM CHLORIDE; TESTOSTERONE;

ADULT; AROUSAL; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; COGNITIVE THERAPY; COMPARATIVE STUDY; HORMONE DETERMINATION; HUMAN; MALE; MASTURBATION; MEDICAL ASSESSMENT; MONITORING; MULTICHANNEL RECORDER; PEDOPHILIA; PHYSIOLOGY; PLETHYSMOGRAPHY; PSYCHOTHERAPY; SELF REPORT; SEXUAL BEHAVIOR;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLICLE STIMULATING HORMONE; HUMANS; LEUPROLIDE; LIBIDO; MALE; MIDDLE AGED; PEDOPHILIA; PENILE ERECTION; PROLACTIN; PROSPECTIVE STUDIES; SEXUAL BEHAVIOR; TESTOSTERONE; TREATMENT OUTCOME;

EID: 29144454485     PISSN: 00040002     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10508-005-7929-2     Document Type: Article

References (45)

1. Abel, G. G., Huffman, J., Warberg, B., & Holland, C. L. (1998). Visual reaction time and plethysmography as measures of sexual interest in child molesters. Sexual Abuse: A Journal of Research and Treatment, 10, 81-95.
2. Abel, G. G., & Osborn, C. (1992). The paraphilias: The extent and nature of sexually deviant and criminal behavior. Psychiatric Clinics of North America, 15, 675-687.
3. American Psychiatric Association. (1994). Diagnosis and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
4. Bambino, T. H., Schreiber, J. R., & Hsueh, A. J. (1980). Gonadotropin-releasing hormone and its agonist inhibit testicular luteinizing hormone receptor and steroidogenesis in immature and adult hypophysectomized rats. Endocrinology, 107, 908-917.
5. Barbaree, H. E., & Mewhort, D. J. (1994). The effects of the z-score transformation on measures of relative erectile response strength: A re-appraisal. Behaviour Research and Therapy, 32, 547-558.
6. Belchetz, P. E., Plant, T. M., Nakai, Y., Keogh, E. J., & Knobil, E. (1978). Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science, 202, 631-633.
7. Berger, P., Berner, W., Bolterauer, J., Gutierrez, K., & Berger, K. (1999). Sadistic personality disorder in sex offenders: Relationship to antisocial personality disorder and sexual sadism. Journal of Personality Disorders, 13, 175-186.
8. Bergquist, C., Nillius, S. J., & Wide, L. (1979). Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent. Lancet, 2, 215-217.
9. Berlin, F. S. (1983). Sex offenders: A biomedical perspective and a status report on biomedical treatment. In J. C. Greer & I. R. Stuart (Eds.), The sexual aggressor: Current perspectives on treatment (pp. 82-123). New York: Van Nostrand Reinhold Company.
10. Bradford, J. M. (1983). The hormonal treatment of sexual offenders. Bulletin of the American Academy of Psychiatry and the Law, 11, 159-169.
11. Bradford, J. M., & Pawlak, A. (1993). Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Archives of Sexual Behavior, 22, 383-402.
12. Briken, P. (2002). Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists [Letter]. Archives of General Psychiatry, 59, 469-470.
13. Briken, P., Hill, A., & Berner, W. (2003). Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. Journal of Clinical Psychiatry, 64, 890-897.
14. Briken, P., Nika, E., & Berner, W. (2001). Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. Journal of Sex and Marital Therapy, 27, 45-55.
15. Brogden, R. N., & Clissold, S. P. (1989). Flutamide: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs, 38, 185-203.
16. Brotherton, J., & Harcus, A. W. (1973). Effect of oral cyproterone acetate on urinary ESH and LH levels in adult males being treated for hypersexuality. Journal of Reproduction and Fertility, 33, 256-257.
17. Byrne, P. M. (2000). The reliability and validity of a less explicit audio and "clothed" visual penile plethysmograph set with child molesters and nonoffenders. Unpublished doctoral dissertation, University of Utah, Salt Lake City, Utah.
18. Clarke, D. J. (1989). Antilibidinal drugs and mental retardation: A review. Medicine, Science, and the Law, 29, 136-146.
19. Cooper, A. J. (1986). Progestogens in the treatment of male sex offenders: A review. Canadian Journal of Psychiatry, 31, 73-79.
20. Cooper, A. J., & Cernovsky, Z. Z. (1994). Comparison of cyproterone acetate (CPA) and leuprolide acetate (LHRH agonist) in a chronic pedophile: A clinical subject study. Biological Psychiatry, 36, 269-271.
21. Epperson, D. L., Kaul, J. D., Huot, S. J., Hesselton, D., Alesander, W., & Goldman, R. (1999). Minnesota Sex Offender Screening Tool Revised (MnSOST-R). St. Paul, MN: Minnesota Department of Corrections.
22. Fagan, P. J., Wise, T. N., Schmidt, C. W., & Berlin, F. S. (2002). Pedophilia. Journal of the American Medical Association, 288, 2458-2465.
23. Gagne, P. (1981). Treatment of sex offenders with medroxyprogesterone acetate. American Journal of Psychiatry, 138, 644-646.
24. Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C., Fleischmann, R. L., Hill, C. L., et al. (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006-1011.
25. Hanson, R. K., Gordon, A., Harris, A. J., Marques, J. K., Murphy, W., Quinsey, V. L., et al. (2002). First report of the collaborative outcome data project on the effectiveness of psychological treatment for sex offenders. Sexual Abuse: A Journal of Research and Treatment, 14, 169-197.
26. Hanson, R. K., & Thornton, D. (1999). Static 99: Improving actuarial risk assessments for sex offenders 1999-02 (National Institute of Corrections Report, Accession Number 015355/Kutak VF 1920.44, pp. 1-23). Ottawa, ON: Canada, Solicitor General of Canada.
27. Hare, R. D. (1998). The PCL-R assessment of psychopathy: Some issues and concerns. Legal and Criminological Psychology, 3, 99-119.
28. Harris, J. T., Rice, M. E., Quinsey, V. L., Chaplin, T. C., & Earls, C. (1992). Maximizing the discriminant validity of phallometric assessment data. Psychological Assessment, 4, 502-511.
29. Heil, P., Ahlmeyer, S., Simons, D., & English, K. (1999). The impact of polygraphy on admissions of crossover offending behavior in adult sexual offenders. Paper presented at the meeting of the ATSA Research and Treatment Conference, Lake Buena Vista, FL.
30. Hirsch, D., Kovatz, S., Bernheim, J., & Shenkman, L. (1994). Fatal fulminant hepatitis from cyproterone acetate. Israel Journal of Medical Sciences, 30, 238-240.
31. Ichikawa, T., Akimoto, S., & Shimazaki, J. (1988). Effect of leuprolide on growth of rat prostatic tumor (R 3327) and weight of male accessory sex organs. Endocrinologia Japonica, 35, 181-187.
32. Kafka, M. (2000). Psychopharmacologic treatments for nonparaphilic compulsive sexual behaviours. CNS Spectrums, 5, 49-59.
33. Kuban, M., Barbaree, H. E., & Blanchard, R. (1999). A comparison of volume and circumference phallometry: Response magnitude and method agreement. Archives of Sexual Behavior, 28, 345-359.
34. Letourneau, E. J. (2002). A comparison of objective measures of sexual arousal and interest: Visual reaction time and penile plethysmography. Sexual Abuse: A Journal of Research and Treatment, 14, 207-223.
35. Linde, R., Doelle, G. C., Alexander, N., Kirchner, F., Vale, W., Rivier, J., et al. (1981). Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: An approach toward the development of a male contraceptive. New England Journal of Medicine, 305, 663-667.
36. Marshall, W. L., & Barbaree, H. E. (1990). Outcome of comprehensive cognitive-behavioral treatment programs. In W. L. Marshall, D. R. Laws, & H. E. Barbaree (Eds.), Handbook of sexual assault: Issues, theories and treatment of the offender (pp. 363-385). New York: Plenum Press.
37. McEvoy, G. K. (1990). AHFS drug information 90. Bethesda, MD: American Society of Hospital Pharmacists.
38. Miner, M. H., & Coleman, E. (2001). Advances in sex offender treatment and challenges for the future. Journal of Psychology and Human Sexuality, 13, 5-24.
39. Murphy, W. D., & Barbaree, H. E. (1994). Assessments of sex offenders by measures of erectile response: Psychometric properties and decision making. Brandon, VT: The Safer Society Press.
40. Raymond, N. C., Grant, J. E., Kim, S. W., & Coleman, E. (2002). Treatment of compulsive sexual behavior with naltrexone and serotonin reuptake inhibitors: Two case studies. International Clinical Psychopharmacology, 17, 201-205.
41. Raymond, N., Robinson, B., Kraft, C., Rittberg, B., & Coleman, E. (2001). Treatment of pedophilia with leuprolide acetate: A case study. Journal of Psychology and Human Sexuality, 13, 79-88.
42. Rosler, A., & Witztum, E. (1998). Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. New England Journal of Medicine, 338, 416-422.
43. Stein, D. J., Hollander, E., Anthony, D. T., Schneier, F. R., Fallon, B. A., Liebowitz, M. R., et al. (1992). Serotonergic medications for sexual obsessions, sexual addiction and paraphilias. Journal of Clinical Psychiatry, 53, 267-271.
44. Vance, M. A., & Smith, J. A. (1984). Endocrine and clinical effects of leuprolide in prostatic cancer. Clinical Pharmacology and Therapeutics, 36, 350-354.
45. Vilchez-Martinez, J. A., Coy, D. H., Arimura, A., Coy, E. J., Hirotsu, Y., & Schally, A. V. (1974). Synthesis and biological properties of (Leu-6)-LH-RH and (D-Leu-6,desGly-NH210)-LH-RH ethylamide. Biochemical and Biophysical Research Communications, 59, 1226-1232.